ArticlePathology oncology research : POR2011
Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival.
Article in Pathology oncology research : POR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 61 citations in OpenAlex.
- Divergent ERα co-factor landscapes in gynecological cancers: implications for disease progression and therapy.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2025Review
- Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance.International journal of molecular sciences · 2024Review
- Article
- Article
- Anticancer Potential of Diruthenium Complexes with Bridging Hydrocarbyl Ligands from Bioactive Alkynols.Inorganic chemistry · 2023Article
- Insights Into the Role of Epigenetic Factors Determining the Estrogen Response in Estrogen-Positive Ovarian Cancer and Prospects of Combining Epi-Drugs With Endocrine Therapy.Frontiers in genetics · 2022Review
- Review
- Effect of Curcumin in Comparison with Trichostatin A on the Reactivation of Estrogen Receptor Alpha gene Expression, Cell Growth Inhibition and Apoptosis Induction in Hepatocellular Carcinoma Hepa 1-6 Cell lLine.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis.Oncotarget · 2017Article
- Screening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis.Oncology letters · 2017Article
- The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.BMC cancer · 2017Article
- Androgen receptor status predicts development of brain metastases in ovarian cancers.Oncotarget · 2017Article
- Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.Cellular oncology (Dordrecht, Netherlands) · 2017Review
- Steroid hormone receptors as prognostic markers in breast cancer.American journal of cancer research · 2017Review
- A transgenic mouse model expressing an ERα folding biosensor reveals the effects of Bisphenol A on estrogen receptor signaling.Scientific reports · 2016Article
- Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.Oncotarget · 2016Article
- Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.Oncotarget · 2016Article
- Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations.Clinical Medicine Insights. Oncology · 2016Review
- EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals.Endocrine reviews · 2015Review
- Estrogen biosynthesis and action in ovarian cancer.Frontiers in endocrinology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estrogen as a potential factor of ovarian carcinogenesis, acts via two nuclear receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), but the cellular signal pathways involved are not completely clear so far. In this study we have described the expression of ERα, detected by immunocytochemistry in 11 ovarian carcinoma cell lines and by immunohistochemistry in 43 Federation Internationale des Gyneacologistes et Obstetristes stage III ovarian carcinoma specimens prepared before and after treatment with cisplatin-based schemes. For cisplatin resistance is a major obstacle in the treatment of ovarian carcinoma, analysis of cisplatin sensitivity in 11 ovarian carcinoma cell line was also performed. The strong nuclear ERα expression was only shown in the single A2780P cell line. Expression of ERα in tissue specimens did not reveal any correlations between histopathological parameters (histologic type and grading). We demonstrated a significant association with ERα expression in specimens from primary laparotomies (PL) and cause-specific survival. In the cases terminated by death of the patient, overall immunoreactivity score of ERα expression at PL was significantly lower than in surviving patients. In addition, Kaplan-Meier analysis revealed significantly shorter overall survival time and progression-free time in cases with lower immunoreactivity score of ERα expression at PL. Our findings support the hypothesis that aberrant hormone activity, by way of altered receptor expression, might be an important factor in the malignant transformation of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.